ekonominyheter

TranslateRSSMobil
Gilead's Hepatitis Drug Sees Sales Slow

Gilead's Hepatitis Drug Sees Sales Slow

Wall Street Journal 28/10 18:39

Gilead Sciences said sales of its blockbuster hepatitis C treatment Sovaldi fell 20% in the third quarter from the June period, hurt by the looming arrival of the company?s latest treatment option.

Till artikeln

Ekonomi Nyheter .se - Innehåll

 

 

 

 

DMCA.com Protection Status